GENOCEA BIOSCIENCES
Genocea Biosciences is a biopharmaceutical company which is engaged in developing novel vaccines and immunotherapies to address diseases with significant unmet needs.Its product candidate includes GEN-003 which is an immunotherapy for the treatment of genital herpes as well as it owns pre-clinical immuno-oncology program focused on personalized cancer vaccines. The company focuses on developing vaccines and immunotherapies for unmet needs through its AnTigen Lead Acquisition System, which is used to design vaccines and immunotherapies. Genocea operates its business through the single segment being Developing and Commercializing vaccines.
GENOCEA BIOSCIENCES
Industry:
Biotechnology Medical
Founded:
2006-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.genocea.com
Total Employee:
51+
Status:
Active
Contact:
3094183917
Email Addresses:
[email protected]
Total Funding:
470.57 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Universal Analytics
Similar Organizations
Crestone
Crestone is a clinical stage biopharmaceutical company focused on inventing and developing novel mechanism.
GeneMedicine
GeneMedicine is a clinical stage biopharmaceutical company focused on developing next-generation viral immunotherapies.
BrightPath Biotherapeutics
BrightPath Biotherapeutics is a stage biopharmaceutical company focused on developing novel cancer immunotherapies.
RegeneRx
RegeneRx is a biopharmaceutical company that designs, researches, and develops novel peptides targeted at diseases with unmet medical needs.
Salix Pharmaceuticals
Salix Pharmaceuticals is a specialty pharmaceutical company focused on the prevention and treatment of gastrointestinal disorders.
Torus Biosystems
Torus Biosystems is a biotech startup that delivers molecular diagnostics for infectious diseases.
Vedanta Biosciences
Vedanta Biosciences creates microbiome-derived therapies to address immune and infectious diseases by modulating the gut microbiota.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Bill & Melinda Gates Foundation
Bill & Melinda Gates Foundation investment in Grant - Genocea Biosciences
Auriga Partners
Auriga Partners investment in Series D - Genocea Biosciences
Morningside Group
Morningside Group investment in Series C - Genocea Biosciences
MP Healthcare Venture Management
MP Healthcare Venture Management investment in Series C - Genocea Biosciences
Auriga Partners
Auriga Partners investment in Series C - Genocea Biosciences
SR One
SR One investment in Series C - Genocea Biosciences
Skyline Ventures
Skyline Ventures investment in Series C - Genocea Biosciences
Sahsen Ventures
Sahsen Ventures investment in Series C - Genocea Biosciences
Lux Capital
Lux Capital investment in Series C - Genocea Biosciences
Johnson & Johnson Development Corporation
Johnson & Johnson Development Corporation investment in Series C - Genocea Biosciences
Official Site Inspections
http://www.genocea.com Semrush global rank: 2.12 M Semrush visits lastest month: 9.59 K
- Host name: 104.21.41.50
- IP address: 104.21.41.50
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Genocea Biosciences"
Genocea Biosciences - Crunchbase Company Profile & Funding
Genocea Biosciences is a biopharmaceutical company which is engaged in developing novel vaccines and immunotherapies to address diseases with significant unmet needs.Its product …See details»
Genocea Biosciences Inc - AnnualReports.com
Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel vaccines and immunotherapies to treat infectious diseases. …See details»
Genocea Initiates Restructuring and Announces Plan to
Apr 28, 2022 Genocea cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties that change over time. These factors include, but are not …See details»
Genocea Biosciences, Inc. - Devex
Learn more about Genocea Biosciences, Inc.'s jobs, projects, latest news, contact information and geographical presence. CORPORATE OVERVIEW Pioneering Neoantigen …See details»
Genocea Initiates Restructuring and Announces Plan to Explore …
CAMBRIDGE, Mass., April 28, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen …See details»
Genocea Announces Wind Down of Operations and Delisting …
CAMBRIDGE, Mass., May 24, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen …See details»
Genocea - Bill & Melinda Gates Foundation
Genocea harnesses the power of T-cells to discover life-changing vaccines and immunotherapies. Since T-cell response is critical during the liver stage of disease, Genocea is identifying …See details»
Genocea Biosciences | GNCA Stock Price, Company Overview
Leading the group were shares of Genocea Biosciences (GNCA), up about 25.7% and shares of Medivation (MDVN) up about 24.6% on the day. Also showing relative strength are drugs …See details»
Genocea Doses First Patient in Phase 1/2a TiTAN Clinical Trial for …
CAMBRIDGE, Mass., July 13, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen …See details»
Genocea Biosciences Provides Corporate Update | BioSpace
Genocea Biosciences Provides Corporate Update | BioSpaceSee details»
Genocea closes up shop after cash reserves dry up
May 24, 2022 Genocea’s quest to find more responsive antigens has come to a close after the company’s financial wick flamed out. As a result, all remaining nonessential staff will be sent packing, and the ...See details»
Genocea Biosciences : Commences Phase 2a Trial for GEN-004, …
Sep 11, 2014 The World Health Organization (WHO) estimates that up to 1.6 million people, including 800,000 children, die each year globally as a result of pneumococcal infection. ...See details»
Genocea Biosciences Provides Corporate Update - GlobeNewswire
Jan 4, 2022 Genocea expects to have initial data from the first five patients later this quarter or early Q2 2022. With eight sites currently accruing patients, Genocea expects to continuously …See details»
Genocea Announces Top-Line Results from Phase 2a Trial for …
Oct 19, 2015 The World Health Organization (WHO) estimates that up to 1.6 million people, including 800,000 children, die annually worldwide from pneumococcal infection. ... Genocea …See details»
Genocea Biosciences Provides Corporate Update - Yahoo Finance
Jan 4, 2022 Enters into Inhibigenâ„¢ R&D collaboration and option agreement with Janssen Reports progress on the GEN-011 TiTANâ„¢ trial CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE …See details»
Genocea Presents Encouraging Initial Data from GEN-011
Apr 8, 2022 Genocea Presents Encouraging Initial Data from GEN-011 Phase 1/2a Trial at AACR 2022 April 08, 2022 13:05 ET | Source: Genocea Biosciences, Inc. Genocea …See details»
Q&A with Genocea: improving cancer treatment with precise, …
Genocea’s ATLAS platform can determine the best target for each individual cancer patient, primarily by identifying and excluding a new type of antigen, called an Inhibigen, which can …See details»
Genocea Introduces GEN-011, a Transformational T cell Therapy
May 12, 2020 --Genocea Biosciences, Inc., a biopharmaceutical company developing next-generation neoantigen immunotherapies, hosted a KOL symposium today with Dr. Eric Tran, …See details»
Genocea Presents Positive GEN-009 Clinical Results, Update on
Nov 9, 2020 --Genocea Biosciences, Inc., a biopharmaceutical company developing next-generation neoantigen immunotherapies, today presented four posters that collectively …See details»
Genocea Presents Encouraging Initial Data from GEN-011 Phase …
Apr 8, 2022 Genocea Biosciences, Inc. GEN-011 shows consistent pattern of activity in first five heavily pre-treated, checkpoint-refractory patients with advanced solid tumors and progressive …See details»